These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

419 related articles for article (PubMed ID: 12696997)

  • 1. Glutamate receptors and Parkinson's disease: opportunities for intervention.
    Marino MJ; Valenti O; Conn PJ
    Drugs Aging; 2003; 20(5):377-97. PubMed ID: 12696997
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Glutamate receptors as therapeutic targets for Parkinson's disease.
    Johnson KA; Conn PJ; Niswender CM
    CNS Neurol Disord Drug Targets; 2009 Dec; 8(6):475-91. PubMed ID: 19702565
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Roles of Glutamate Receptors in Parkinson's Disease.
    Zhang Z; Zhang S; Fu P; Zhang Z; Lin K; Ko JK; Yung KK
    Int J Mol Sci; 2019 Sep; 20(18):. PubMed ID: 31500132
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prospects of glutamate antagonists in the therapy of Parkinson's disease.
    Blandini F; Greenamyre JT
    Fundam Clin Pharmacol; 1998; 12(1):4-12. PubMed ID: 9523179
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Glutamate and Parkinson's disease.
    Blandini F; Porter RH; Greenamyre JT
    Mol Neurobiol; 1996 Feb; 12(1):73-94. PubMed ID: 8732541
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Glutamate/dopamine D1/D2 balance in the basal ganglia and its relevance to Parkinson's disease.
    Starr MS
    Synapse; 1995 Apr; 19(4):264-93. PubMed ID: 7792721
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prolonged blockade of NMDA or mGluR5 glutamate receptors reduces nigrostriatal degeneration while inducing selective metabolic changes in the basal ganglia circuitry in a rodent model of Parkinson's disease.
    Armentero MT; Fancellu R; Nappi G; Bramanti P; Blandini F
    Neurobiol Dis; 2006 Apr; 22(1):1-9. PubMed ID: 16289868
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Striatal metabotropic glutamate receptors as a target for pharmacotherapy in Parkinson's disease.
    Bonsi P; Cuomo D; Picconi B; Sciamanna G; Tscherter A; Tolu M; Bernardi G; Calabresi P; Pisani A
    Amino Acids; 2007 Feb; 32(2):189-95. PubMed ID: 16715415
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Glutamatergic influences on the basal ganglia.
    Greenamyre JT
    Clin Neuropharmacol; 2001; 24(2):65-70. PubMed ID: 11307040
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antagonism of metabotropic glutamate receptor type 5 attenuates l-DOPA-induced dyskinesia and its molecular and neurochemical correlates in a rat model of Parkinson's disease.
    Mela F; Marti M; Dekundy A; Danysz W; Morari M; Cenci MA
    J Neurochem; 2007 Apr; 101(2):483-97. PubMed ID: 17359492
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Therapeutic potential of targeting glutamate receptors in Parkinson's disease.
    Finlay C; Duty S
    J Neural Transm (Vienna); 2014 Aug; 121(8):861-80. PubMed ID: 24557498
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Drugs used to treat Parkinson's disease, present status and future directions.
    Abdel-Salam OM
    CNS Neurol Disord Drug Targets; 2008 Oct; 7(4):321-42. PubMed ID: 18991661
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New pharmacological avenues for the treatment of L-DOPA-induced dyskinesias in Parkinson's disease: targeting glutamate and adenosine receptors.
    Blandini F; Armentero MT
    Expert Opin Investig Drugs; 2012 Feb; 21(2):153-68. PubMed ID: 22233485
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interaction of adenosine receptors with other receptors from therapeutic perspective in Parkinson's disease.
    Morin N; Di Paolo T
    Int Rev Neurobiol; 2014; 119():151-67. PubMed ID: 25175965
    [TBL] [Abstract][Full Text] [Related]  

  • 15. NMDA antagonists as Parkinson's disease therapy: disseminating the evidence.
    Majláth Z; Vécsei L
    Neurodegener Dis Manag; 2014; 4(1):23-30. PubMed ID: 24640976
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of metabotropic glutamate receptors in animal models of Parkinson's disease.
    Senkowska A; Ossowska K
    Pol J Pharmacol; 2003; 55(6):935-50. PubMed ID: 14730087
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antiparkinsonian actions of ifenprodil in the MPTP-lesioned marmoset model of Parkinson's disease.
    Nash JE; Fox SH; Henry B; Hill MP; Peggs D; McGuire S; Maneuf Y; Hille C; Brotchie JM; Crossman AR
    Exp Neurol; 2000 Sep; 165(1):136-42. PubMed ID: 10964492
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antiparkinsonian actions of CP-101,606, an antagonist of NR2B subunit-containing N-methyl-d-aspartate receptors.
    Steece-Collier K; Chambers LK; Jaw-Tsai SS; Menniti FS; Greenamyre JT
    Exp Neurol; 2000 May; 163(1):239-43. PubMed ID: 10785463
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Levodopa enhances synaptic plasticity in the substantia nigra pars reticulata of Parkinson's disease patients.
    Prescott IA; Dostrovsky JO; Moro E; Hodaie M; Lozano AM; Hutchison WD
    Brain; 2009 Feb; 132(Pt 2):309-18. PubMed ID: 19050033
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Subtype selective antagonism of substantia nigra pars compacta Group I metabotropic glutamate receptors protects the nigrostriatal system against 6-hydroxydopamine toxicity in vivo.
    Vernon AC; Zbarsky V; Datla KP; Croucher MJ; Dexter DT
    J Neurochem; 2007 Nov; 103(3):1075-91. PubMed ID: 17714448
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.